Q Therapeutics and REPROCELL Partnering on Stem Cell-based Therapies for ALS
Q Therapeutics of the United States and REPROCELL of Japan are teaming up to develop stem cell-based therapies for central nervous system diseases such as ALS and transverse myelitis, or TM.
The collaboration will meld Q Therapeutics’ expertise in nerve cell therapy with REPROCELL’s expertise in stem cell treatments.
“This collaboration with Q Therapeutics and their scientific co-founder, Dr. Mahendra Rao, enables us to accelerate our therapeutic regenerative medicine business using iPS [induced pluripotent stem] cells,” Dr. Chikafumi Yokoyama, the CEO of REPROCELL, said in a press release. “I am also honored to step into contributing to unmet medical needs like ALS and TM using our proprietary iPS cell technology.”